A Phase I study to evaluate the safety and dosimetry of 68Ga-OncoACP3 in patients with prostate cancer

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515608-38-00

Acronym

PH-ACP3GA-01/24

Enrollment

Registered

2024-11-27

Start date

2025-03-19

Completion date

2025-10-03

Last updated

2025-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

a progressive and confirmed serum PSA level > 0.2 ng/mL) -metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands, Patients with prostate cancer with: -suspected metastasis who are candidates for initial definitive therapy -suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e.

Interventions

None listed

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Countries

Italy

Outcome results